{"entity":{"id":"noetik","kind":"company","name":"Noetik","aka":[],"tldr":"Noetik builds artificial intelligence models of tumours from huge sets of tissue images and molecular data, to predict which patients will respond to a cancer drug and to find new targets.","summary":"Noetik, founded in 2023 in South San Francisco, is an AI-native biotechnology company that has assembled one of the largest multimodal tumour datasets (spatial transcriptomics, proteomics, histology and genomics from patient samples) plus its Perturb-map in vivo functional genomics platform. On these it trains foundation models of the tumour microenvironment, including OCTO-VirtualCell, Celleporter and TARIO-2, which identifies likely responders to the checkpoint combination botensilimab plus balstilimab from routine pathology images (June 2026, following a 2025 biomarker collaboration with Agenus). Applications span trial enrichment, repositioning of clinical-stage drugs and novel target discovery. In January 2026 GSK licensed Noetik's foundation models in an anchor partnership reported at USD 50 million. Noetik raised a USD 14 million seed led by DCVC (2023) and a USD 40 million Series A (2024).","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.noetik.ai"},{"label":"News (Series A, GSK partnership)","url":"https://www.noetik.ai/news"},{"label":"DCVC leads USD 14 million seed","url":"https://www.dcvc.com/news-insights/dcvc-leads-14-million-seed-round-to-support-noetik/"}],"tags":[],"related":[],"cancers":[],"sections":["ai-computation","drug-discovery"],"technologies":["single-cell-spatial","pathology-foundation-model","ai-drug-design"],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Series A lead investor not named on fetched pages (Business Wire release blocked). Investor names other than DCVC come from logos on the company homepage."],"hq":"South San Francisco, CA","country":"US","companyType":"ai-software","website":"https://www.noetik.ai","founded":2023,"stage":"startup","investors":["dcvc","polaris-partners","khosla-ventures"],"funding":[{"round":"Seed","year":2023,"amountUsd":14000000,"source":"https://www.dcvc.com/news-insights/dcvc-leads-14-million-seed-round-to-support-noetik/","note":"Led by DCVC"},{"round":"Series A","year":2024,"amountUsd":40000000,"source":"https://www.noetik.ai/news"}]},"route":"/companies/noetik/","neighbours":{"section":[{"id":"ai-computation","kind":"section","name":"AI & Computation","route":"/fronts/ai-computation/"},{"id":"drug-discovery","kind":"section","name":"Drug Discovery Platforms","route":"/fronts/drug-discovery/"}],"technology":[{"id":"ai-drug-design","kind":"technology","name":"AI-driven drug & target discovery","route":"/technologies/ai-drug-design/"},{"id":"pathology-foundation-model","kind":"technology","name":"Pathology & radiology foundation models","route":"/technologies/pathology-foundation-model/"},{"id":"single-cell-spatial","kind":"technology","name":"Single-cell & spatial profiling","route":"/technologies/single-cell-spatial/"}],"company":[{"id":"dcvc","kind":"company","name":"DCVC","route":"/companies/dcvc/"},{"id":"khosla-ventures","kind":"company","name":"Khosla Ventures","route":"/companies/khosla-ventures/"},{"id":"polaris-partners","kind":"company","name":"Polaris Partners","route":"/companies/polaris-partners/"}],"roadmap":[{"id":"ai-oncology-roadmap","kind":"roadmap","name":"AI in oncology roadmap: pattern readers → foundation models → agents in the workflow","route":"/roadmaps/ai-oncology-roadmap/"}],"term":[{"id":"virtual-cell-models","kind":"term","name":"Virtual cell models and in-silico perturbation screens","route":"/terms/virtual-cell-models/"}]}}